To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
PHASE2
This study is a randomized, active control, open-label, phase 2 trial. Erlo...
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
PHASE2
This randomized phase II trial studies OPT-821 and vaccine therapy to see h...
Status
Completed
Location
University of South Alabama Mitchell Cancer Institute